pohaus

06:24

pohaus Premium Updated 

This stock is providing a massive upside with extremely limited risk for long term downside.

02:06

pohaus Premium

RLX Technologies Inc is the largest e-cigarette company in China. The head of it is the former head of Uber China. The hair cur in the share price is on the back of a report for potential regulation/taxation of e-cigarettes. Even a tax equivalent doesn't effect the growth drivers much and this seems more like a paid bash attempt by a short seller. I don't see...

08:25

pohaus Premium

Rekor Systems makes vehicle ID and skip tracing technology that is used by public safety, cities, states and private enterprise to ID and process transactions for motorists. I think the value case is here and we have the added benefit of an aggressive growth company. Two of the standouts from their quarterly call was the co-branded insurance portal function...

08:45

pohaus Premium

$LOTZ , CarLotz inc is in the same space as giants $CVNA, $VRM, and competitor $SFT Unlike those three they have a unique vehicle sourcing model. (Fleet consignment.) They also have no inventory carry costs and a way lower cost per acquisition. They recently raised $305 million at $10 per share. The company has been around for 10 years and is already profitable...

06:22

pohaus Premium

I think LOTZ inc has the potential to return over 100% in a short amount of time. I will update this idea as it progresses.

pohaus Premium

$AKBA is a heavily shorted bio-technology company that recently won DOD funding for one of their phase three candidates. I think the bullish trend is just getting started and a real shove will add 100% or more to the price of the stock.

05:41

pohaus Premium

Inseego is the leader in 5G router and hotspots. They have contracts with several major carriers and the earnings that will push this stock to new highs are not baked into the price yet. On top it has 28% short interest which can be a major catalyst for a squeeze to higher prices.

03:58

pohaus Premium

They came out with better than expected revenue but worse than expected earnings. Since this is a stock driven by both I expect there to be a substantial dip in the share price for the next few days at least. The other pressures exerted on the markets are going to come in the form of rebalance/margin calls that are going to cause funds and investors alike to have...

06:03

pohaus Premium

I think Fulgent Genetics is extremely cheap and institutional investors are just barely starting to take notice. The near term catalysts for massive upside are already in play and not priced into the stock.

03:34

pohaus Premium

This can still run more if we close above $61 look for next target to $77 then $85

05:10

pohaus Premium

Price and volume analysis of Arcturus Therapeutics

02:38

pohaus Premium

I think this stock presents a massive risk/reward scenario. The upside here is 1500% plus and the downside is 10% or 150/1 I will update this trade with more information as I get it.

02:38

pohaus Premium

I am still a believer in the long term prospects for this company. I took profits because I think it may come under selling pressure when the convertible note converts to common stock. Something that will take place over the next couple weeks. // ---> Here is a paragraph from yesterdays share holder notice: The Company’s expected use of proceeds from the Notes...

05:12

pohaus Premium

Progenity has been long from $3.68. It almost hit the first take profit target of $8 intra-day. Will update the next target when that becomes support.

02:03

pohaus Premium

This trade fell through my stop-out point. I will re-evaluate as it finds support.

05:16

pohaus Premium

I think the short term thesis here is really strong and the mid-term thesis is also strong.

11:07

pohaus Premium

Details about how we get to $19 and what might hold us back.

pohaus Premium

I am bullish this stock for a number of reasons. Partially the back stop of capital they have and partially the sector they play it. This is an EV play essentially.